Angiodynamics Inc 's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Angiodynamics Inc 's ROA in the fourth quarter of 2026?
Angiodynamics Inc recorded a cumulative net loss of $-37 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -12.89%.

However, within the Healthcare sector 327 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the May 31 2026 quarter, so far to 3252, from total ROA ranking in the third quarter of 2026 at 3747.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(May 31 2026) IV. Quarter	(Feb 28 2026) III. Quarter	(Nov 30 2025) II. Quarter	(Aug 31 2025) I. Quarter	(May 31 2025) IV. Quarter
Y / Y Total Assets Change	19.17 %	-8.67 %	-11.81 %	-9.53 %	-11.81 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-37	-31	-28	-32	-34
Return On Assets (TTM)	-12.89 %	-11.55 %	-9.97 %	-11.18 %	-11.55 %
ANGO's Total Ranking	# 3252	# 3747	# 3317	# 3355	# 3453
Total Assets (TTM) in million	334	261	280	266	280
Seq. Total Assets Change	28.07 %	-6.95 %	5.46 %	-5.18 %	-1.85 %
Seq. Net Income Change	-	-	-	-	-

ANGO's 5 Years Annual ROA >> Back to ANGO Management Effectiveness >> Compare ANGO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 105
Sector	# 328
Overall	# 3293

Return On Assets Statistics
High	Average	Low
8.14 %	-7.8 %	-71.69 %
(May 31 2019)		(Nov 30 2024)

Financial Statements
Angiodynamics Inc 's Assets	$ 334 million	ANGO's Balance sheet
Angiodynamics Inc 's Income	$ -11 million	Quarterly ANGO's Income Statement
ANGO's Income by Division		See ANGO's Income by Division

Annual Return On Assets	(May 31 2026) FY 2026	(May 31 2025) FY 2025	(May 31 2024) FY 2024	(May 31 2023) FY 2023	(May 31 2022) FY 2022
Y / Y Total Assets Change	19.17 %	-11.81 %	-40.36 %	-3.64 %	-1.55 %
Total Assets in million	334	280	318	533	553
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-37	-34	-184	-52	-27
Annual Return On Assets	-11.01 %	-12.13 %	-58.03 %	-9.85 %	-4.8 %

ANGO's 5 Years Annual ROA >> Back to ANGO Management Effectiveness >> Compare ANGO ROA to its Competitors

More Return On Assets Ratios
ANGO's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ANGO's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ANGO's Competitors
Subscribers only: Roa for Angiodynamics Inc 's Suppliers
Subscribers only: Return On Assets for ANGO's Customers

You may also want to know
ANGO's Roi	ANGO's Inventory Turnover Ratio	ANGO's Growth Rates	ANGO's Dividend Comparisons
	ANGO's Profitability Ratios	ANGO's Asset Turnover Ratio	ANGO's Dividend Growth
ANGO's Roe	ANGO's Valuation Ratios	ANGO's Financial Strength Ratios	ANGO's Dividend Payout Ratio

Companies with similar Return On Assets at May 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:22:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.